Steward Partners Investment Advisory’s Rubius Therapeutics, Inc RUBY Stock Holding History

Steward Partners Investment Advisory’s Portfolio RUBY Stock Details RUBY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-200	Closed	-$35	–	3461
2022 Q4	$35	Buy	+200	New	+$55	﹤0.01%	3328
2018 Q4	–	Sell	-350	Closed	-$8K	–	2338
2018 Q3	$8K	Buy	+350	New	+$8K	﹤0.01%	1990

Other funds holding RUBY

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

SOMRS

State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

CGL

Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return

Steward Partners Investment Advisory's RUBY Position: Q1 2023 in Review

Steward Partners Investment Advisory sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2023, closing a stake of 200 shares — an estimated $35 sold.

Steward Partners Investment Advisory first reported a position in RUBY in Q3 2018 and held it in 2 quarters. The position peaked at $8K in Q3 2018. 7 funds tracked by Wall St. Rank hold RUBY as of Q1 2023.

Steward Partners Investment Advisory reported no remaining Rubius Therapeutics, Inc position as of Q1 2023 after selling out during the quarter.
Steward Partners Investment Advisory sold 200 Rubius Therapeutics, Inc shares in Q1 2023, an estimated $35.
Steward Partners Investment Advisory first reported a position in Rubius Therapeutics, Inc in Q3 2018 and held it in 2 quarters.
Steward Partners Investment Advisory's Rubius Therapeutics, Inc position peaked at $8K in Q3 2018.
7 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2023.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2023, filed 15 May 2023.